COVID-19 Evidence Alerts
from McMaster PLUSTM

Current best evidence for clinical care (more info)

COVID-19 Evidence Alerts needs your support. If our service is of value to you, please consider donating to keep it going. Learn more Donate now

Treatment Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2020 Dec 24. pii: 13993003.03725-2020. doi: 10.1183/13993003.03725-2020.

Nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro However, there is no evidence of its impact on SARS-CoV-2 infection.In a multicenter, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue) were enrolled. After confirmation of SARS-CoV2 infection by RT-PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, TID, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biomarkers of inflammation, and hospitalisation rate. Adverse events were also assessed.From June 8 to August 20, 2020, 1575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analysed. Median time from symptom onset to first dose of study drug was 5 (4-5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009). Viral load was also reduced after nitazoxanide compared to placebo (p=0.006). The percent viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed.In patients with mild Covid-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.

Discipline / Specialty Area Score
Emergency Medicine
General Internal Medicine-Primary Care(US)
Family Medicine (FM)/General Practice (GP)
Comments from MORE raters

Emergency Medicine rater

This moderate sized randomized trial with a significant number of patients lost to follow up failed to find any hint of clinical benefit with nitazoxanide for COVID-19 patients. Small decreases in viral load compared to placebo are likely clinically meaningless. This is a another fail at identifying a breakthrough treatment for COVID-19.

Emergency Medicine rater

This is useful information for every physician working at COVID-19 clinics.

Family Medicine (FM)/General Practice (GP) rater

If this was being purported widespread as a treatment, it may be newsworthy. However, with lack of a seeming clinically important outcome and lack of intention to treat analysis, I don't see this as specifically newsworthy unless these results are noted as a review of current treatment possibilities that have been studied.